Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.
How this was made
The 30-second read
Why it matters
Two Canadian Notices of Allowance broaden protection across both priority franchises and reinforce a global patent estate (~250 issued/pending). The press release also specifies expected patent term end dates (Jan 2039 for Actimab-A+CLAG-M and Oct 2038 for Iomab-ACT).
Market read
For ATNM, the news is a tangible IP milestone in Canada for two key programs, modestly improving durability/defensibility while leaving clinical catalysts as the bigger drivers.
What to watch
Actual patent issuance timing is still “expected in the ordinary course,” and the market may focus more on upcoming Phase 2/3 milestones and financing/clinical execution than on IP paperwork.
Background
Actinium is developing targeted radiotherapies and conditioning agents; its Actimab-A program targets AML in combination with CLAG-M, while Iomab-ACT is a CD45-based conditioning approach for gene-edited cell therapies.
Ticker impact
Actinium announced CIPO Notices of Allowance for two patent applications covering Actimab-A+CLAG-M and Iomab-ACT conditioning in Canada.
Mild positive bias; likely supportive for sentiment but not a direct near-term earnings catalyst.
Patent allowance/issuance is incremental versus clinical readouts, but it adds concrete, market-specific protection (Canada) and extends term into 2038–2039 for the named claims.
Market effects
Reinforces the value of IP strategy in targeted radiotherapies and cell-therapy conditioning platforms; may support peer sentiment around patent estate building.
Improves Actinium’s Canadian protection for AML combination immunotherapy and CD45 conditioning for gene-edited cell therapies.
Adds to an already multi-jurisdiction patent footprint (US/Japan/Europe/China pending), reducing perceived geographic IP risk.
Counterpoint
Patent allowances may already be anticipated by the market; without clinical data, the incremental impact on valuation can be limited.
Key entities
- companyActinium Pharmaceuticals, Inc.
Subject of the press release; received Canadian patent Notices of Allowance for two priority radiotherapy/cell-therapy conditioning programs.
- regulatorCanadian Intellectual Property Office (CIPO)
Issued Notices of Allowance for the two Actinium patent applications; issuance expected in the ordinary course.
